Viewing Study NCT06728618

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:57 AM
Ignite Modification Date: 2026-02-23 @ 1:12 AM
Study NCT ID: NCT06728618
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-12-11
First Post: 2024-12-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
Sponsor: Shanghai Zhongshan Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Oral Squamous Cell Carcinoma (OSCC) View
None Oropharyngeal Squamous Cell Carcinoma (SCC) View
None Resectable Oral and Oropharyngeal Squamous Cell Carcinoma View
None Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma View
Keywords: